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Background: 5% of first time pregnancies are complicated by pre-eclampsia, the leading cause of maternal
death in Europe. No clinically useful screening test exists; consequentially clinicians are unable to offer targeted
surveillance or preventative strategies. IMPROvED Consortium members have pioneered a personalised medicine
approach to identifying blood-borne biomarkers through recent technological advancements, involving mapping of
the blood metabolome and proteome. The key objective is to develop a sensitive, specific, high-throughput and
economically viable early pregnancy screening test for pre-eclampsia.
Methods/Design: We report the design of a multicentre, phase IIa clinical study aiming to recruit 5000 low risk
primiparous women to assess and refine innovative prototype tests based on emerging metabolomic and
proteomic technologies. Participation involves maternal phlebotomy at 15 and 20 weeks’ gestation, with optional
testing and biobanking at 11 and 34 weeks. Blood samples will be analysed using two innovative, proprietary
prototype platforms; one metabolomic based and one proteomic based, both of which outperform current
biomarker based screening tests at comparable gestations. Analytical and clinical data will be collated and analysed
via the Copenhagen Trials Unit.
Discussion: The IMPROvED study is expected to refine proteomic and metabolomic panels, combined with clinical
parameters, and evaluate clinical applicability as an early pregnancy predictive test for pre-eclampsia. If ‘at risk’
patients can be identified, this will allow stratified care with personalised fetal and maternal surveillance, early
diagnosis, timely intervention, and significant health economic savings. The IMPROvED biobank will be accessible
to the European scientific community for high quality research into the cause and prevention of adverse
pregnancy outcome.
Trial registration: Trial registration number NCT01891240
The IMPROvED project is funded by the seventh framework programme for Research and Technological
development of the EU. http://www.fp7-improved.eu/
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An estimated 50 million babies are born to first time
mothers worldwide every year, with 2.4 million in the 27
European Union countries [1]. Almost 1 in 20 of these
pregnancies are complicated by pre-eclampsia, a disease
of late pregnancy, characterized by the concomitant oc-
currence of hypertension and proteinuria.
The condition is associated globally with 70,000–80,000
maternal and over 500,000 infant deaths annually. For the
mother it can lead to acute problems in the liver, kidneys,
brain and the clotting system. Pre-eclampsia is the most
important cause of maternal death in Europe, account-
ing for 17–24% of all maternal deaths [2]. Additionally,
epidemiological studies have demonstrated that pre-
eclampsia is associated with an increased risk of cardio-
vascular and metabolic diseases later in the mother’s life
[3,4]. A quarter of the babies born to mothers with
pre-eclampsia are growth restricted and a third are pre-
mature; pre-eclampsia accounts for approximately 20%
of neonatal intensive care unit costs. The child may have
problems with neurocognitive development that can result
in mild learning difficulties through to severe disabilities.
Being born growth restricted also predisposes the child to
cardiovascular disease as an adult [5].
Every year, an estimated €31 billion is spent in the de-
veloped world on direct healthcare costs to provide
antenatal care for nulliparous women and treatment for
pre-eclampsia; of this, an estimated €9 billion is spent in
Europe [6]. The healthcare costs of one case of pre-
eclampsia are estimated to exceed €15,000 (all maternal
and neonatal hospital costs, not accounting for longer
term implications for the baby) [6]. An effective screen-
ing test would facilitate stratification and targeting of
limited resources [6]. Preliminary analyses suggest that
an effective test which halves antenatal visits, followed
by the administration of aspirin, for screen positive wo-
men, (which reduces the incidence of disease by 20–25%
[7]) would be of significant economic benefit if the unit
cost of a screening test is €400–€800.
Pre-eclampsia is a heterogeneous condition with re-
spect to the onset and severity of the clinical manifesta-
tions, this has hampered the development of screening
strategies and the development and assessment of poten-
tial preventive interventions.
Circulating factors predate the clinical signs; in pre-
eclampsia there are demonstrable biologically active cir-
culating factors that are apparent well before the clinical
presentation of the disease [8]. Nevertheless, there are
currently no early pregnancy predictive tests for pre-
eclampsia. Numerous candidate biomarkers (>200 stud-
ies so far) have been proposed for prediction of disease,
including placental hormones, angiogenic factors, and
lipids [9]. However, none (nor any combination) has
emerged with the adequate specificity and sensitivity to beof clinical use. Indeed the World Health Organization’s
(WHO) systematic review assessed the usefulness of clini-
cal, biophysical, and biochemical tests in the prediction of
pre-eclampsia and concluded that there is no cost effective
or reliable screening test for pre-eclampsia [10]. Without
such a screening test, clinicians are unable to offer either
targeted surveillance or potential preventative therapies to
those at greatest risk.
The IMPROvED consortium is a new and distinctive
partnership of four small and medium enterprises
(SMEs) and eight academic institutions, with comple-
mentary and world leading expertise. We are a diverse
group of obstetric academics, laboratory and social sci-
entists, entrepreneurs, regulators, practitioners, clini-
cians, biostatisticians and health economists from across
Europe and beyond, and we will be supported by end-
user patient support groups. All IMPROvED partners
in this consortium are motivated by the current absence
of a clinically useful screening test for pre-eclampsia.
Through a multi-centre hospital-based study, representa-
tive of different healthcare models, we will establish a high
calibre pregnancy bio-bank for European pregnancy re-
searchers. We will then utilise a dual strategy of dis-
tinct but complementary cutting edge platforms to
measure novel metabolomic biomarkers (MetTest) and
proteomic biomarkers (ProTest) which we have previously
identified as predictive of disease [11,12]. The develop-
ment of such a personalised medicine approach, that of-
fers first time mothers accurate risk assessment for
pre-eclampsia, will radically impact the provision of
antenatal care, both in Europe and the rest of the
world, and will reduce the clinical complications of
the leading cause of maternal death in Europe.
Methods/Design
IMPROvED is a multicentre, European phase IIa clinical
study, with clinical centres in Ireland, U.K, Germany,
Sweden and the Netherlands. During the 2 year study
period 5000 low risk, nulliparous women will be recruited
between 9 + 0–16 + 6 weeks’ gestation (See details Table 1).
The primary outcome is pre-eclampsia. Preeclampsia is
defined as gestational hypertension (systolic BP ≥ 140
mmHg and/or diastolic BP ≥90 mmHg (Korotkoff V) on
at least 2 occasions 4 h apart after 20 weeks’ gestation,
but before the onset of labour or postpartum systolic
BP ≥ 140 mmHg and/or diastolic BP ≥90 mmHg on at
least 2 occasions 4 h apart with proteinuria (≥ 300 mg/
24 h or spot urine protein:creatinine ratio ≥ 30 mg/mmol
creatinine, or urine dipstick protein > = ++) (Table 2).
To maximise the utility of the IMPROvED biobank
for the scientific community, other primary outcomes
include spontaneous pre-term birth <37 + 0 weeks,
and small for gestational age babies <10th customised
centile (See Table 2 for exclusion criteria).
Table 1 Recruitment targets by centre
Centre Recruits
Cork 1000
Keele 1000
Liverpool 500
Stockholm 750
Rotterdam 1000
Cologne 750
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Logistics for recruitment will be adapted to suit indivi-
dual centres participating in the study. Women will be
referred through a number of routes including referral
by their midwife, obstetrician or general practitioner and
self-referral following exposure to the study through
friends, posters, advertisements, website and news sto-
ries. Maternity caregivers in each centre will be encour-
aged to provide information about the study to eligible
women in early pregnancy. Attempts will be made to re-
cruit women from all socioeconomic and ethnic groups
in the participating centres. Maternal age and ethnicity
will be recorded on women who are approached to par-
ticipate but decline, and data compared with those who
consent to participate. All patients recruited must con-
sent to sampling at the second (15 week) and third (20
week) time-points. The first (11 week) and fourth (34
week) time-points are desirable but not mandatory.
Blood specimens will be collected at all sites. At certain
sites urine specimens, hair from women, DNA fromTable 2 Exclusion criteria
• Unsure of LMP and unwilling to have USS at≤ 20 weeks
• ≥ 3 miscarriages
• ≥3 terminations
• Known or suspected major fetal anomaly/abnormal karyotype
• Essential hypertension treated pre-pregnancy
• Moderate-severe hypertension at booking (BP >160/100 mmHg)
• Diabetes
• Renal disease
• Systemic Lupus Erythematosus
• Anti-phospholipid syndrome
• Sickle cell disease
• HIV positive
• Major uterine anomaly
• Cervical suture in situ
• Knife cone biopsy
• Long term steroids
• Treatment with low-dose aspirin
• Treatment with heparin/low molecular weight heparinparticipants, partners and DNA samples from the baby
at birth will also be collected (Figure 1).
First sampling (optional)
At the first visit (11 + 0 to 13 + 6 weeks’ gestation), eligi-
bility will be confirmed, informed consent signed and
these data entered into the database. Maternal measure-
ments will be performed and entered in the database.
Blood specimens will be collected and information about
the specimens will be entered into the database.
Second and third samplings (essential)
At the 15-week visit (14 + 0 to 16 + 6 weeks’), the
woman will be interviewed and information entered dir-
ectly into the database on demographics, current preg-
nancy details and smoking and alcohol habits. Maternal
measurements (See details Figure 1) will be performed
and entered in the database. Blood specimens will also
be collected and all data will be entered directly into the
database.
At the 20-week visit (19 + 0 to 21 + 6 weeks’ gestation)
blood specimens will be collected and maternal mea-
surements (See details Figure 1) will be performed. All
data will be entered directly into the database. Partici-
pants will be instructed to contact the research midwife
if she delivers before the final visit or if she develops one
of the pregnancy endpoints.
Fourth sampling (optional)
At the final visit (32 + 0 to 34 + 6 weeks’ gestation) blood
specimens will be collected and maternal measurements
(See details Figure 1) will be performed. All data will be
entered directly into the database. Participants will
be instructed to contact the research midwife when
she delivers or if she develops one of the pregnancy
endpoints.
Partner’s participation
At certain sites, participants’ partners will also be re-
cruited. At any of the visits, or by extra appointment,
partners will give one blood sample for DNA analysis.
At birth
At certain sites, blood from the umbilical cord, a sample
of the cord itself and placental samples will be taken
shortly after delivery.
Pregnancy outcome
Where possible, a research midwife will see each parti-
cipant within 72 hours following delivery. Information
about pregnancy events since the final visit but before
the birth will be obtained. Information will also be ob-
tained about the delivery, the baby and maternal and in-
fant outcome in the postnatal period. If seen within 72
Figure 1 Flowchart of IMPROvED visits and pregnancy outcome data.
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be obtained from the medical records. The information
will be confirmed by review of her medical records and
entered onto the database.
Participant status at the time of delivery will be re-
corded in the final pregnancy outcome Case Report
Form (CRF) as either continuing in the study, a fetal
death, a termination after 20 weeks’ gestation or with-
drawn/lost to follow up from the study. Information
about pregnancy complications will also be recorded.
A decision will be made as to whether each womandevelops one or more of the primary endpoints. All
participants who develop pre-eclampsia, deliver a SGA
baby or experience spontaneous pre-term birth will have
detailed clinical, laboratory and outcome data collec-
ted. Each woman and baby’s data will be systematically
reviewed 6–8 weeks following her expected date of deli-
very to ensure accuracy.
Sample collection and biobank
Serum and plasma specimens will be split into 0.25 ml
aliquots, labelled with a unique barcode. Each barcode,
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base. Aliquots of different types of specimens will be
colour coded and the aliquots will be stored in the −80°C
freezers within 3 hours of collection. The freezers will be
equipped with remote alarm systems, monitored 24/7 and
study personnel responsive to any alarm. Aliquots from
each recruitment centre will be transferred (at −80°C) to
Metabolomics Diagnostics (Cork, Ireland) and Pronota
(Ghent, Belgium) for determination of metabolomics and
proteomic biomarkers and thus assessment of the per-
formance of MetTest and ProTest [11,12]. The remaining
aliquots will be transferred to the IMPROvED biobank,
housed at the University of Cork, and will be available to
the European scientific community for high quality re-
search into the cause and prevention of adverse pregnancy
outcome.
Database
The database will have a biobank facility with separate
forms for each type of participant specimen collected at
each visit. The aliquot barcodes and biobank database
will ensure that the storage position and usage of all ali-
quots will be able to be tracked.
The data system will be built to the same security and
confidentiality standards as those of hospital electronic
patient records. Innovative features of the informatics
platform are that demographic, clinical, biochemical, ge-
nomic and diagnostic data can all be stored within the
same architecture, and can be co-visualized for compari-
sons. The novel approach of personalised medicine will
be applied by following a path for the individual in the
biobank and clinical data through the aggregation of the
information in the risk assessment algorithms, leading
back to the individualised risk assessment of that par-
ticular patient. All data are stored in a secure manner
within a remotely accessible electronic database.
Furthermore, the informatics platform will provide a
database for the study biobank to enable rapid sample
entry (by barcode) and sample retrieval. This system also
allows a unique subject identifier to be linked with the
sample identifiers within the biobank to allow rapid se-
lection and to support secondary studies. A system to
enable users to perform ad-hoc queries on collected
data, select specimens based on ad-hoc set of clinical at-
tributes of the subjects and their values as well as speci-
men features will be developed.
Ethics
The Ethics Advisory Board (EAB) for the IMPROvED
study will be chaired by Dr Deirdre Madden at Uni-
versity College Cork. Other members include Professor
Lesley McCowan at the University of Auckland, New
Zealand, Professor Robert Shaw at the University of
Nottingham, UK and Xavier Carne at the University ofBarcelona, Spain. The EAB will liaise closely with the
Copenhagen Trial Unit and the Study Coordinator to
ensure that the study is performed to the highest ethical
standard.
Informed written consent will be obtained from all
women participating in the study. All participating cen-
tres have obtained approval for the study from their re-
spective ethic committees.
Statistical analysis
We will independently examine the predictive power of
ProTest and MetTest. We will mine the proteomic and
metabolomic data for algorithms which have the poten-
tial to generate greater sensitivity and specificity. Any
such algorithms will be incorporated into future studies.
We will also evaluate the combinatorial power of pro-
teomics and metabolomics based tests (augmented by
clinical data), to enhance the prognostic specificity and
sensitivity. One of the models we will specifically explore
is a sequential model of screening for pre-eclampsia,
with MetTest at 15 weeks gestation followed by ProTest
at 20 weeks. Such a sequential screening model is akin
to that employed for Downs’ Syndrome; first trimester
screening is followed by screening at 15–18 weeks. Sta-
tistical significance will be reported with both P values
and confidence intervals at 95%.
Power calculations
Power calculations have been considered extensively.
Given the complexity of the study, there is no single
simple solution. For the purpose of sample size estima-
tion of the overall study, we used a binary outcome and
associated measures of sensitivity and likelihood ratio
as determinants of the value of these tests. Although
the predictive algorithms will produce a continuous risk
score, the use of a categorical outcome fits with the final
binary decision process (to treat or not to treat) based on
the risk score.
Based on the lowest estimated prevalence of pre-
eclampsia of 3%, a test sensitivity of 93% and a specifi-
city of 97%, then we need to recruit 4800 women to be
90% certain that the true specificity of the patient popu-
lation is no less than 95%. Thus, allowing for patient
dropout, a study population of 5,000 women should be
sufficiently powered.
Discussion
A considerable body of evidence demonstrates that
many late pregnancy complications have their foun-
dations in early pregnancy, and much work in pre-
eclampsia has focussed on this premise [13]. However,
some studies of tests for placental dysfunction indi-
cate a temporal relationship between biochemical and
ultrasonic measurements, and evolution of pregnancy
Figure 2 The effect of study design on sample size calculations and conclusions that can be drawn from screening studies. (A) Women
are randomised to having or not having the screening test performed. (B) Women have the screening test performed and those who screen as
high risk are randomised to having an intervention or having the result concealed.
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samples across all trimesters will facilitate assessment of
gestational age dependence for risk-assessment. Tests that
can predict preeclampsia across gestations, including near
term, may be more applicable to different models of ante-
natal care, including lower income settings [14]. Addition-
ally, contributing biobank samples from all trimesters will
provide a valuable resource for research into adverse preg-
nancy outcomes.
A viable screening programme requires accurate iden-
tification of women at high risk early in the disease
process, and effective interventions to modify risk, and
improve outcomes [14]. These fundamental components
are contentious in pre-eclampsia. A sufficiently discri-
minatory test, has yet to be detailed. Although aspirin
reduces the risk of pre-eclampsia in high risk women
by 20–25%, there is no highly active disease modifying
therapy.
Smith argues that failure to develop more effective
screening methods is partly due to limitations in re-
search methodology [14]. If cost-effectiveness of scree-
ning tests is to be evaluated in randomised trials, two
study designs should be considered i.e. randomisation
prior to, or after the application of a screening test
(Figure 2). These two designs address very different re-
search questions. In the context of pre-eclampsia screen-
ing, randomisation confined to screen positive women,
to intervention (aspirin) vs. no intervention (placebo)
allows adequate effectiveness assessment of interven-
tion (aspirin), but not of the whole screen and treatprogramme. The only way to adequately assess the impact
of the whole pre-eclampsia screening programme would
be to compare it with the randomly allocated unscreened
population for full cost-effectiveness analysis. The im-
pact of screening tests developed in the context of
the IMPROvED study will be suitable for assessment
by either study design.
In summary, we describe the pragmatic design for a
European multicentre phase IIa clinical study to assess
the clinical applicability of predictive testing for pre-
eclampsia in low risk women, and the establishment of a
European biobank. The design will allow assessment of
the predictive performance of the proteomic and meta-
bolomic tests throughout pregnancy. Blood samples ob-
tained in all trimesters will maximise the usefulness of the
IMPROvED biobank for European pregnancy research.
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